Compare UG & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | DARE |
|---|---|---|
| Founded | 1942 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 24.4M |
| IPO Year | N/A | N/A |
| Metric | UG | DARE |
|---|---|---|
| Price | $6.62 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 14.9K | ★ 76.3K |
| Earning Date | 03-20-2026 | 03-30-2026 |
| Dividend Yield | ★ 7.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $10,060,322.00 | N/A |
| Revenue This Year | N/A | $3,843.33 |
| Revenue Next Year | N/A | $8,700.33 |
| P/E Ratio | $15.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.58 | $1.61 |
| 52 Week High | $11.08 | $9.19 |
| Indicator | UG | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 38.07 |
| Support Level | $6.25 | $1.68 |
| Resistance Level | $7.41 | $2.02 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 32.58 | 16.06 |
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.